Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 4, 2011, Pages 281-288

  Koh, Kyung Nam ^a   Park, Meerim ^a   Kim, Bo Eun ^a   Bae, Keun Wook ^a   Im, Ho Joon ^a   Seo, Jong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; alternative donor; childhood

Indexed keywords

CYCLOSPORIN; METHOTREXATE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOGENETICS; DONOR; ENGRAFTMENT; EVENT FREE SURVIVAL; FEMALE; GENETIC RISK; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HISTOCOMPATIBILITY; HUMAN; INFANT; KARYOTYPE; LEUKEMIA RELAPSE; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SEROLOGY; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOGENETIC ANALYSIS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; PREDICTIVE VALUE OF TESTS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79955523646     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318203e279     Document Type: Article

References (37)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030-1043. (Pubitemid 351389536)
2. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005; 19:2025-2029. (Pubitemid 41741594)
3. Rubnitz JE. Childhood acute myeloid leukemia. Curr Treat Options Oncol. 2008;9:95-105.
4. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333. (Pubitemid 28452973)
5. Gupta V. Alternative donor transplants for high-risk acute myeloid leukemia. Curr Opin Hematol. 2008;15:115-120. (Pubitemid 351323151)
6. ter Bals E, Kaspers GJL. Treatment of childhood acute myeloid leukemia. Expert Rev Anticanc. 2005;5:917-929.
7. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. 2007; 12:341-355. (Pubitemid 46562369)
8. Fagioli F, Zecca M, Locatelli F, et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol. 2008;30: 575-583.
9. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562 (Pubitemid 20069191)
10. The NCCN Clinical Practice Guidelines in Oncologyt Acute Myeloid Leukemia (Version 1). http://www.nccn.org/professionals/ physician-gls/PDF/aml.pdf. Accessed July 2009.
11. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol. 2002;118:385-400. (Pubitemid 34994639)
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
13. Deeg HJ, Antin JH. The clinical spectrum of acute graftversus- host disease. Semin Hematol. 2006;43:24-31. (Pubitemid 43063332)
14. Socie G. Chronic graft-versus-host disease: clinical features and grading systems. Int J Hematol. 2004;79:216-220. (Pubitemid 38620768)
15. Klingebiel T, Reinhardt D, Bader P. Place of HSCT in treatment of childhood AML. Bone Marrow Transplant. 2008; 42(suppl 2):S7-S9.
16. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008;26:5797-5801.
17. Reinhardt D, Kremens B, Zimmermann M, et al. No improvement of overall-survival in children with high-risk acute myeloid Leukemia by stem cell transplantation in 1st complete remission. ASH Annual Meeting Abstracts 2006;108:320.
18. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349-2361.
19. Ortega JJ, Diaz de Heredia C, Olive T, et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica. 2003;88: 290-299. (Pubitemid 36358717)
20. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007-4013.
21. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007; 109:4641-4647. (Pubitemid 46827753)
22. Aladjidi N, Auvrignon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol. 2003;21:4377-4385. (Pubitemid 46621815)
23. Gale RP, Horowitz MM, Rees JK, et al. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996;10:13-19. (Pubitemid 26052974)
24. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant. 2000;26:397-404. (Pubitemid 30649555)
25. Wells RJ, Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. J Clin Oncol. 2003;21:2940-2947. (Pubitemid 46621845)
26. Ishaqi MK, Afzal S, Dupuis A, et al. Outcome of allogeneic hematopoietic stem cell transplantation for children with acute myelogenous leukemia in second complete remission: single center experience. Pediatr Transplant. 2009;13:999-1003.
27. Nemecek ER, Gooley TA, Woolfrey AE, et al. Outcome of allogeneic bone marrow transplantation for children with advanced acute myeloid leukemia. Bone Marrow Transplant. 2004;34:799-806. (Pubitemid 39467892)
28. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371-4383.
29. Lee JH, Yoon HS, Song JS, et al. Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution. J Korean Med Sci. 2009;24: 904-909.
30. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813-1826.
31. Smith FO, Alonzo TA, Gerbing RB, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia. 2005;19: 2054-2062. (Pubitemid 41741597)
32. Shenoy S, Smith FO. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant. 2008;41:141-148. (Pubitemid 351188911)
33. Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004;103:3655-3661. (Pubitemid 38596278)
34. Kim HJ, Min WS, Eom KS, et al. Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. Bone Marrow Transplant. 2007;40:1069-1074.
35. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood. 2003;102:470-476. (Pubitemid 36841962)
36. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26:577-584. (Pubitemid 351264351)
37. Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood. 2008;111:1044-1053. (Pubitemid 351213382)